RSV can be serious.
Study vaccines may offer protection.

Seeking healthy adults age 65+ for vaccine studies enrolling now.

Those who qualify may receive*:

  • Payment up to $650, which varies by study

Plus, no cost to you.
No health insurance or referral needed.

Ready to get started? Click Here.

Respiratory Syncytial Virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two. However, RSV can be serious, especially for infants and older adults with health problems.

  • RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the U.S.
  • RSV also causes serious respiratory illness in older adults, especially those age 65 and older with chronic heart or lung diseases or weakened immune systems.
  • RSV is also more severe for people with asthma, COPD and congestive heart failure.

Right now, the only prevention for RSV is hand washing and keeping surfaces clean and disinfected, or avoiding close contact with sick people and staying home when sick.

Scientists are working on vaccines to prevent RSV and you could make a difference as a volunteer.

Take the next step to see if you qualify for local RSV Vaccine research studies for healthy people age 65+.   But don’t delay — space is limited!

* In a research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from a doctor/research team for the duration of the study. For studies that offer compensation, reasonable payments will be made for participation. The length of the study may vary.

Ready to get started?

Click Here.

How does it work?

1

Tell us a little bit about yourself

2

Answer some questions about your health

3

We will connect you to available studies in your area

Just takes a few minutes

AcurianHealth

AcurianHealth helps connect people with research studies that offer treatment under development. Since 1998, AcurianHealth has referred 1 million study candidates to 800 studies in 70 countries.